In Vitro Platelet Production via Genetic Circuit Engineering
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing platelets in vitro are inefficient, as they fail to replicate the endogenous bone marrow environment effectively, limiting the production capacity and understanding of hematopoietic stem cell (HSC) differentiation, particularly for megakaryocytes (MK) and platelet production.
Innovation Solution
Employing synthetic biology to engineer genetic circuits and microenvironments that mimic the natural extrinsic and intrinsic cues regulating HSC proliferation and differentiation, using CRISPR/Cas9 technology to insert genetic circuits at specific loci, and controlling cytokine secretion and transcription factor expression to enhance platelet production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional in vitro methods are used to produce platelets, then the process is simple, but the production capacity is limited and cannot effectively replicate bone marrow environment
Solution Approach 1:
The patent implements nesting by placing hematopoietic stem cells within a 3D microenvironment structure that replicates bone marrow architecture. The microenvironment includes nested layers of support cells, extracellular matrix components, and spatial organization that mimic the hierarchical structure of bone marrow, enabling efficient platelet production while maintaining biological fidelity.
Solution Approach 2:
The invention uses composite materials by combining multiple cell types (hematopoietic stem cells, support cells), extracellular matrix components, and signaling molecules into an integrated microenvironment system. This composite approach creates a functional replica of bone marrow that enhances platelet production capacity while managing system complexity through modular design.
2Quantity of substance
If in vitro production methods are used, then human donation risks are minimized, but the ability to produce large volumes of purified platelets is limited
Solution Approach 1:
The patent applies segmentation by dividing the platelet production process into distinct functional stages: stem cell expansion, differentiation, and platelet release. The microenvironment is segmented into specialized zones with different support cells and signaling molecules that guide each stage, enabling efficient production of large volumes of purified platelets while minimizing donation risks.
Solution Approach 2:
The invention implements feedback mechanisms through signaling molecules and extracellular matrix components that dynamically regulate cell proliferation and differentiation based on real-time conditions. This feedback system optimizes platelet production efficiency and volume by adjusting cellular behavior in response to microenvironmental cues, ensuring high yields while maintaining safety.
3Loss of information
If genetic circuits are engineered into feeder cells to control differentiation, then understanding of HSC differentiation mechanisms is enhanced, but the device complexity increases
Solution Approach 1:
The patent uses genetic circuits as intermediary elements that translate complex differentiation signals into controllable gene expression patterns. These circuits act as mediators between external control signals and internal cellular responses, enabling systematic investigation of HSC differentiation mechanisms while managing complexity through modular genetic design.
Solution Approach 2:
The invention applies parameter changes by using inducible promoters and controllable genetic circuits that allow dynamic adjustment of gene expression levels and timing. This enables systematic variation of differentiation parameters (temporal expression, spatial distribution, dosage) to uncover mechanistic insights while maintaining manageable system complexity through standardized genetic tools.
Data Source
AI summary
Disclosed herein are methods of producing platelets and red blood cells using synthetic biology and uses thereof. The methods disclosed herein can also be used to produce platelets and red blood cells comprising a therapeutic agent. The cells produced by the methods disclosed herein can be used to treat, manage, prevent and diagnosis various diseases and disorders and be used as a research tool.